Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see i...

Descripción completa

Detalles Bibliográficos
Autores principales: Motzer, Robert J., Russo, Paul, Grünwald, Viktor, Tomita, Yoshihiko, Zurawski, Bogdan, Parikh, Omi, Buti, Sebastiano, Barthélémy, Philippe, Goh, Jeffrey C., Ye, Dingwei, Lingua, Alejo, Lattouf, Jean-Baptiste, Albigès, Laurence, George, Saby, Shuch, Brian, Sosman, Jeffrey, Staehler, Michael, Vázquez Estévez, Sergio, Simsek, Burcin, Spiridigliozzi, Julia, Chudnovsky, Aleksander, Bex, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Summary of Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517884/
https://www.ncbi.nlm.nih.gov/pubmed/37659025
http://dx.doi.org/10.1007/s11523-023-00987-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517884/
https://www.ncbi.nlm.nih.gov/pubmed/37659025
http://dx.doi.org/10.1007/s11523-023-00987-1

Ejemplares similares